Personalis is a cancer genomics company transforming the development of therapies by providing molecular data about each patient's cancer and immune response. Co. designed its NeXT Platform to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on the human genes, together with the immune system, in contrast to several cancer panels that cover roughly 50 to 500 genes. Co. is also developing a complementary liquid biopsy assay that analyzes all of the human genes versus the narrowly focused liquid biopsy assays that are available. The PSNL stock yearly return is shown above.
The yearly return on the PSNL stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2020 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the PSNL annual return calculation with any dividends reinvested as applicable (on ex-dates).
|